Eculizumab: Completed Phase III enrollment

ALXN completed enrollment of >75 patients in the double-blind, placebo-controlled, international Phase III TRIUMPH trial to treat PNH. ALXN has an SPA for the trial. The compound has Orphan Drug desig...